The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1311
May 4, 2009
View Complete Issue         Table of Contents 2019 
Fenofibric Acid (Trilipix)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Fenofibric Acid (Trilipix)
May 4, 2009 (Issue: 1311)
The FDA has approved the marketing of fenofibric acid (Trilipix - Abbott) to reduce triglycerides and increase HDL-C in patients with mixed dyslipidemia on optimal doses of a HMG-CoA reductase inhibitor (statin) who have, or have risk factors for,...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Fenofibric Acid (Trilipix)
Article code: 1311a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.